Herrero Payo J A, Montes Díaz M J, Páez Borda A, Sánchez Sánchez E, Moreno Valle J A, Berenguer Sánchez A
Servicio de Urología, Hospital Universitario de Getafe, Madrid, España.
Arch Esp Urol. 1996 Jul-Aug;49(6):595-606.
A population of Spanish men aged over 49 years were screened for prostate cancer. The detection rate and the clinical features of the tumors found are analyzed.
The study comprised two phases: Phase I: Subjects were evaluated by digital rectal examination (DRE) and prostate-specific antigen (PSA) was determined. Phase II: Subjects with a positive DRE or PSA > 4 ng/ml were evaluated by transrectal US. If PSA was > 10 ng/ml or DRE or transrectal US were abnormal, a transrectal biopsy was performed; most of these were sextant. PSA density was used as a criterion for biopsy in subjects with PSA 4-10 ng/ml and normal DRE and transrectal US. From June, 1993 to August 1994, 1091 subjects have been evaluated.
对年龄超过49岁的西班牙男性人群进行前列腺癌筛查。分析所发现肿瘤的检出率及临床特征。
该研究包括两个阶段:第一阶段:通过直肠指检(DRE)对受试者进行评估,并测定前列腺特异性抗原(PSA)。第二阶段:DRE阳性或PSA>4 ng/ml的受试者接受经直肠超声检查。如果PSA>10 ng/ml或DRE或经直肠超声检查异常,则进行经直肠活检;大多数为六分区活检。PSA密度被用作PSA 4 - 10 ng/ml且DRE和经直肠超声检查正常的受试者进行活检的标准。从1993年6月至1994年8月,共评估了1091名受试者。
1)平均年龄为59.32岁;379人(34.7%)有排尿症状较轻。2)DRE和PSA异常的分别占5.07%和9.07%;135名(12.4%)DRE和/或PSA可疑的受试者接受了经直肠超声检查。3)在进行的97次活检(8.8%)中,仅11例(1%)检测到前列腺癌;每检测出1例前列腺癌需要进行8.8次活检。4)临床上,7例肿瘤(63.6%)为局限性,4例(36.3%)为晚期。
1)参与率较低(21%)。2)PSA平均值随年龄增加。前列腺体积是对PSA变化影响最大的因素。3)PSA检测出的肿瘤(10例;90.9%)比DRE(8例;72.7%)多。约27.27%的病变由PSA检测出而DRE未检测出,9.09%仅由DRE检测出。4)检出率较低(1.008%);PSA为0.91%,DRE为0.73%,经直肠超声检查为51%(n = 135)。5)我们检测出的临床晚期肿瘤(36.6%)比其他系列研究更多,可能是因为这是首次在该人群中进行此类研究。鉴于上述结果,我们不主张常规开展这些研究。或许在后续更长随访期的研究中,对于潜在可治愈的局限性肿瘤可实现更高的检出率。